Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
I am looking for
added new label for I am looking for
Advanced Filters
Found 11 clinical trials
Extracorporeal Photopheresis for Medicare Recipients of Lung Allografts

The primary aims of this study is to determine the efficacy and tolerability of Extracorporeal Photopheresis (ECP) for the treatment of either refractory (240) or newly diagnosed (739

  • 25 Jan, 2021
  • 21 locations
Extracorporal Photopheresis Pilot Study

ECP will be given to the patients [UVAR®XTS TM Therakos system, Johnson & Johnson] according to the following schedule: Starting at day 21 after transplant, if hematologic recovery allowed it: 2 ECP per week the first 2 weeks, and 1 ECP per week during 1 month. Total = 8 ECP …

myeloablative conditioning
allogeneic transplantation
  • 07 Nov, 2020
  • 1 location
Extracorporeal Photopheresis and Early Cardiac Graft Vasculopathy

therapeutic options, like extracorporeal photopheresis are lately being investigated. Unlike conventional coronary angiography, optical coherence tomography (OCT) is able to detect the development of

  • 23 Jan, 2021
  • 1 location
Extracorporeal Photopheresis for Acute Graft Versus Host Disease

The purpose of this research study is to evaluate the safety and feasibility of extracorporeal photopheresis (ECP) in the treatment of steroid-refractory acute graft-versus-host disease

acute graft-versus-host disease
chronic graft versus host disease
graft versus host disease
hla matching
extracorporeal photopheresis
  • 07 Nov, 2020
  • 1 location
Itacitinib (INCB039110) and Extracorporeal Photopheresis (ECP) for First-Line Treatment in Chronic GVHD

An open-label, Phase II trial designed to assess the recommended phase 2 dose (RP2D) of itacitinib in combination ECP and efficacy of the combination after 24 weeks of therapy. The trial will consist of two parts: Part One will assess the RP2D. For dose-finding purposes, the DLT evaluation period will …

  • 12 Feb, 2021
  • 1 location
Extracorporeal Photopheresis of Patients With Crohn's Disease Using 5-aminolevulinic Acid

In the clinical trial the investigators will assess efficacy, safety and tolerability after single and multiple doses of 3 millimolar 5 aminolevulinic acid (Gliolan) in combination with blue-light (405 nanometer) or red-light (630 nm) photopheresis in patients with active crohns disease. The study is a proof-of-concept pilot with 10 included …

faecal calprotectin
  • 03 Feb, 2021
  • 1 location
Modification of Extracorporeal Photopheresis in Cutaneous T-cell Lymphoma or Chronic Graft-versus-host Disease

Extracorporeal photopheresis (ECP), is commonly used for the treatment of cutaneous T-cell lymphoma (CTCL) and chronic graft-versus-host disease. ECP (cGVHD) is an immune modulating treatment

  • 26 Jan, 2021
  • 1 location
Extracorporeal Photopheresis Using Theraflex ECP for Patients With Refractory Chronic Graft Versus Host Disease (cGVHD)

The present project is a prospective, multicenter, non-randomized, phase II trial which aims to evaluate the clinical impact and the safety of extracorporeal photopheresis (ECP) using the

  • 21 Jan, 2021
  • 6 locations
Coronary Artery Disease After Heart Transplantation

This study evaluates coronary artery disease after heart transplantation and its relation to platelet function. Furthermore, we will evaluate extracorporeal photopheresis as treatment of

  • 23 Jan, 2021
  • 1 location
The Influence of Extracorporeal Photopheresis on Skin Sclerosis

Extracorporeal photopheresis (ECP), also known as extracorporeal photoimmunotherapy or photochemotherapy, is a leukapheresis-based therapy that has been in clinical use for over three decades

  • 21 Feb, 2021